ProCE Banner Activity

Myeloproliferative Neoplasms: What’s New for 2019?

Clinical Thought
How will new and forthcoming clinical data change the management of essential thrombocythemia, polycythemia vera, and myelofibrosis? Here’s my take.

Released: February 25, 2019

Expiration: February 24, 2020

No longer available for credit.

Share

Faculty

Srdan Verstovsek

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Celgene

Incyte Corporation

Faculty Disclosure

Primary Author

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Srdan Verstovsek, MD, PhD, has disclosed that he has received consulting fees from Celgene, Constellation, Incyte, Novartis, Pragmatist, and Sierra and funds for research support from Blueprint Medicines, Celgene, CTI BioPharma, Genentech, Gilead Sciences, Incyte, Novartis, NS Pharma, Promedior, and Roche.